Skip to main content

IsoPlexis Corporation (ISO)

IsoPlexis will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Chart not available yet
Market Capn/a
Revenue (ttm)12.01M
Net Income (ttm)-36.76M
Shares Outn/a
EPS (ttm)n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Openn/a
Previous Closen/a
Day's Rangen/a
52-Week Rangen/a
Betan/a
Analystsn/a
Price Targetn/a
Est. Earnings Daten/a

About ISO

IsoPlexis is enabling deeper access to in vivo biology and driving durable and potentially transformational research on disease in a new era of advanced medicine. Our single cell proteomics platform, which includes instruments, chip consumables and software, provides an end-to-end solution to reveal a more complete view of protein function at an individual cellular level. Since our commercial launch in June of 2018, our platform has been adopted by the top 15 global biopharmaceutical companies by revenue and nearly half of the comprehensive can...

IndustryLaboratory Analytical Instruments
IPO DatePending
CEOSean Mackay
Employees313
Stock ExchangeNASDAQ
Ticker SymbolISO
Full Company Profile

Financial Performance

In 2020, IsoPlexis's revenue was $10.39 million, an increase of 38.40% compared to the previous year's $7.51 million. Losses were -$23.26 million, 70.7% more than in 2019.

Financial Statements

News

Proteomics platform IsoPlexis files for a $100 million IPO

IsoPlexis, which provides a single cell proteomics platform for drug development, filed on Tuesday with the SEC to raise up to $100 million.

2 months ago - NASDAQ

IsoPlexis IPO Registration Document (S-1)

IsoPlexis Corporation has filed to go public with an IPO on the NASDAQ.

2 months ago - SEC